Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$7.88 USD
+0.06 (0.77%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $7.88 0.00 (0.00%) 6:44 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Brokerage Reports
Ironwood Pharmaceuticals, Inc. [IRWD]
Reports for Purchase
Showing records 941 - 960 ( 1015 total )
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Upgrading to NEUTRAL from UNDERPERFORM; Adjusting Estimates for the Recently Completed Financing and Linzess Script Metrics
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Raising Another $150M-Plus in Equity, Another $200M Needed to Bridge to Profitability, in Our View, Reiterate UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology/Biopharmaceuticals/BioDefense-New Drug Launch Weekly Retail Sales Tracker - Week Ending May 10
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
LINZESS Weekly Retail Sales Tracker - Week Ending May 10
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
New Drug Launch Weekly Retail Sales Tracker - Week Ending May 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology/Biopharmaceuticals/BioDefense - New Drug Launch Weekly Retail Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
New Drug Launch Weekly Retail Sales Tracker - Week Ending April 19
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Downgrading to UNDERPERFORM and Lowering Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Earnings Preview: LINZESS Q1:13 End - User Demand $15M - Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
LINZESS Weekly Retail Sales Tracker - Q1:13 Linzess End User Demand $15M vs. our $15M Estimate
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
New Drug Launch Weekly Retail Sales Tracker - Week ending March 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C